Affymetrix Posts 2 Percent Q1 Revenue Growth | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Affymetrix reported after the close of the market on Monday that its first-quarter 2010 revenues increased 2 percent, with a sharp increase in product sales somewhat offset by lower service revenues.

The Santa Clara, Calif.-based firm brought in total revenues of $80.2 million for the three-month period ended March 31, compared to revenues of $78.6 million for the first quarter of 2009. Affy beat analysts' consensus estimate of $78.9 million in revenues for Q1 2010.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.